NCT01046682View on ClinicalTrials.gov

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
HIVEndothelial DysfunctionInflammationInsulin Resistance
Interventions
DRUG

Salsalate

Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.

Trial Locations (1)

44106

University Hospitals Case Medical Center, Cleveland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University Hospitals Cleveland Medical Center

OTHER